Scarica l'app Stockscreener
25.57
1.27%
0.32
Dopo l'orario di chiusura:
25.71
0.14
+0.55%
Precedente Chiudi:
$25.25
Aprire:
$25.6
Volume 24 ore:
156.83K
Relative Volume:
0.61
Capitalizzazione di mercato:
$185.75M
Reddito:
$32.73M
Utile/perdita netta:
$-19.52M
Rapporto P/E:
-4.626
EPS:
-5.5275
Flusso di cassa netto:
$-24.61M
1 W Prestazione:
-18.59%
1M Prestazione:
-5.16%
6M Prestazione:
+373.78%
1 anno Prestazione:
+18.61%
Intervallo 1D:
$24.67
$25.92
Intervallo di 1 settimana:
$24.13
$32.07
Portata 52W:
$4.971
$45.50
Cue Biopharma Inc Stock (CUE) Company Profile
Nome
Cue Biopharma Inc
Settore
Industria
Telefono
617-949-2680
Indirizzo
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
25.57 | 228.18M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-13 | Iniziato | Jefferies | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2022-11-21 | Iniziato | Piper Sandler | Overweight |
| 2022-01-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-03 | Iniziato | Craig Hallum | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-04-09 | Iniziato | Stifel | Buy |
| 2020-01-28 | Iniziato | BTIG Research | Buy |
| 2020-01-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Cue Biopharma Inc Borsa (CUE) Ultime notizie
B.Riley reiterates Cue Biopharma stock rating on allergy data By Investing.com - Investing.com Canada
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast - GlobeNewswire Inc.
Cue Biopharma,Phase 2 Primary and Key Seco - Moomoo
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response - Yahoo Finance
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart? - Insider Monkey
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CUE) 2026-09-24 - Seeking Alpha
Cue Biopharma (CUE) Short Interest & Short Float | Updated Sep 2026 $CUE - MarketBeat
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer - GlobeNewswire Inc.
China syndrome? Phase II wins for Cue in CSU, stock melts down - BioWorld News
Cue Biopharma stock swings after positive CUE-221 Phase 2 data and profit-taking - AD HOC NEWS
Cue Biopharma rated Buy after positive phase 2 results show superior efficacy in treating chronic spontaneous urticaria. - Pluang
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win For CSU With Novel Dual MOA - Seeking Alpha
B. Riley's Buy Rating on Cue Biopharma (CUE) Highlights Market's High Price-to-Sales Expectations - GuruFocus
Cue Biopharma Announces Positive Phase 2 Results for CUE-221 in Chronic Spontaneous Urticaria - Kalkine Media
Cue Biopharma (CUE) Shares Drop 31% After Phase 2 Trial Results Despite Promising Efficacy - GuruFocus
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset - Seeking Alpha
What's Going on With Cue Biopharma Stock on Monday? - benzinga.com
Cue Biopharma (CUE) Surges 41.7% Pre-Market Amid Market Rally an - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com
Cue Biopharma reports positive Phase 2 topline results for CUE-221 in CSU, durable benefit vs placebo and omalizumab - TradingView
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results - Yahoo Finance
Why is Cue Biopharma stock surging today? By Investing.com - Investing.com Canada
Cue Biopharma, Inc.(NasdaqCM: CUE) added to S&P Global BMI Index - marketscreener.com
Cue Biopharma (CUE) Reports Positive Phase 2 Data, Market Pricin - GuruFocus
Cue Biopharma reports positive phase 2 results for CUE-221 By Investing.com - Investing.com Canada
Cue Biopharma Reports Positive Phase 2 Topline Results for CUE-221 in Chronic Spontaneous Urticaria - Quiver Quantitative
Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria - TradingView
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria - GlobeNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE) - Eastern Progress
Cue Biopharma (CUE) Stock Gains on B. Riley Buy Rating Amid High P/S Valuation - gurufocus.com
Cue Biopharma is a new Buy at B. Riley on valuation - TradingView
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
CUE Initiated Coverage On by B. Riley Securities -- Price Target $83.00 - GuruFocus
Cue Biopharma Price Target Announced at $83.00/Share by B. Riley Securities - Moomoo
Cue Biopharma stock initiated at Buy by B.Riley on allergy drug potential - Investing.com Nigeria
Enterprise value to EBIT forward of Cue Biopharma, Inc. – SWB:1UC0 - TradingView
Cue Biopharma (CUE) Slides 8.21% to $28.00, Testing Support Near $26.60Volatility Skew - dars.gov.et
Cue Biopharma Inc (CUE) Financials FY2025: Revenue $27.5M, Net Loss $26.6M - Stock Titan
Shao-Lee Lin Discloses Investment at Cue Biopharma with 6.2% Stake - TradingView
Cue Biopharma (CUE) CEO builds stake with stock awards and cheap warrants - Stock Titan
Cue Biopharma, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Driehaus Capital Management Acquires New Stake in Cue Biopharma Inc (CUE) - GuruFocus
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock - Investing.com
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock By Investing.com - Investing.com South Africa
Cue Biopharma legal chief sells $265,627 in common stock - Investing.com
Cue Biopharma legal chief sells $265,627 in common stock By Investing.com - Investing.com Canada
Cue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 5,628 Shares of Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) Insider Sells $265,664.61 in Stock - MarketBeat
Cue Biopharma (NASDAQ: CUE) exec's tax sell-to-cover after equity grant - Stock Titan
Cue Biopharma (CUE) Q2 Results Highlight High Price-to-Sales Ami - GuruFocus
Cue Biopharma (CUE) Leaps 10.04% to $34.2, Testing Key Resistance at $35.91Seasonality Effect - Vinanet
Cue Biopharma Inc Azioni (CUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cue Biopharma Inc Azioni (CUE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ray Sumita | Chief Legal Compliance Officer |
Aug 13 '26 |
Sale |
30.09 |
8,829 |
265,628 |
118,545 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer |
Aug 13 '26 |
Option Exercise |
0.00 |
13,647 |
0 |
54,589 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer |
Aug 13 '26 |
Sale |
30.09 |
5,628 |
169,324 |
48,961 |
| Lin Shao-Lee | Chief Executive Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
109,179 |
0 |
764,253 |
| Lin Shao-Lee | Chief Executive Officer |
Aug 12 '26 |
Sale |
27.10 |
40,000 |
1,083,989 |
724,253 |
| Lin Shao-Lee | Chief Executive Officer |
Aug 13 '26 |
Sale |
28.62 |
18,258 |
522,573 |
705,995 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):